Interpretation of the China Guidelines for the Prevention and Treatment of Diabetes （2024 Edition）

Yin Jingxia, Yu Li, Pu Danlan, Xu Xiaoli, Liao Yong

PDF(681 KB)
PDF(681 KB)
Journal of Chongqing Medical University ›› 2025, Vol. 50 ›› Issue (05) : 557-564. DOI: 10.13406/j.cnki.cyxb.003749
Endocrine Regulation and Metabolic Diseases

Interpretation of the China Guidelines for the Prevention and Treatment of Diabetes （2024 Edition）

Author information +
History +

Abstract

In recent years，significant progress has been made in diabetes research both domestically and internationally，new diagnosis and treatment techniques and methods have been constantly emerging，and clinical research evidence has been continuously accumulated and updated. To keep pace with these important developments，the Diabetes Branch of the Chinese Medical Association has actively organized experts to update the China Guidelines for the Prevention and Treatment of Diabetes. This update aims to provide a more comprehensive and scientific guide for diabetes prevention and treatment，greatly promote the standardized and integrated management of diabetes by clinicians，and ensure that patients receive standardized and personalized treatment plans to improve therapeutic outcomes and quality of life.

Key words

diabetes / diagnosis / treatment / interpretation of guidelines

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
Yin Jingxia , Yu Li , Pu Danlan , et al . Interpretation of the China Guidelines for the Prevention and Treatment of Diabetes （2024 Edition）. Journal of Chongqing Medical University. 2025, 50(05): 557-564 https://doi.org/10.13406/j.cnki.cyxb.003749

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis
1
中华医学会糖尿病学分会. 中国糖尿病防治指南（2024版）[J]. 中华糖尿病杂志，2025，17（1）：16-139.
Chinese Diabetes Society. Guideline for the prevention and treatment of diabetes mellitus in China（2024 edition)[J]. Chin J Diabetes Mellit， 2025，17（1）：16-139.
本文引用 [3]
2
中华医学会糖尿病学分会. 中国2型糖尿病防治指南（2020年版）[J]. 中华糖尿病杂志，2021，13（4）：315-409.
Chinese Diabetes Society. Guideline for the prevention and treatment of type 2 diabetes mellitus in China（2020 edition）[J]. Chin J Diabetes Mellit，2021，13（4）：315-409.
本文引用 [1]
3
廖涌. 中国糖尿病的流行病学现状及展望[J]. 重庆医科大学学报，2015，40（7）：1042-1045．
Liao Y. Epidemiology and research advances in diabetes mellitus in China[J]. J Chongqing Med Univ，2015，40（7）：1042-1045．
本文引用 [1]
4
Wang LM， Peng W， Zhao ZP，et al. Prevalence and treatment of diabetes in China，2013-2018[J]. JAMA，2021，326（24）：2498-2506．
本文引用 [3]
5
Wang LM， Gao P， Zhang M，et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013[J]. JAMA，2017，317（24）：2515-2523．
本文引用 [1]
6
Mayer-Davis EJ， Dabelea D， Lawrence JM. Incidence trends of type 1 and type 2 diabetes among youths，2002-2012[J]. N Engl J Med，2017，377（3）：301．
本文引用 [1]
7
Dabelea D， Mayer-Davis EJ， Saydah S，et al. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009[J]. JAMA，2014，311（17）：1778-1786．
本文引用 [1]
8
罗说明，周智广. 《成人隐匿性自身免疫糖尿病诊疗中国专家共识（2021版）》解读[J]. 中华糖尿病杂志，2022，14（1）：17-20．
Luo SM， Zhou ZG. Interpretation of Consensus of Chinese experts on the diagnosis and treatment of latent autoimmune diabetes in adults（2021 Edition）[J]. Chin J Diabetes Mellit，2022，14（1）：17-20.
本文引用 [1]
9
Copeland KC， Zeitler P， Geffner M，et al. Characteristics of adolescents and youth with recent-onset type 2 diabetes：the TODAY cohort at baseline[J]. J Clin Endocrinol Metab，2011，96（1）：159-167．
本文引用 [1]
10
Beltrand J， Elie C， Busiah K，et al. Sulfonylurea therapy benefits neurological and psychomotor functions in patients with neonatal diabetes owing to potassium channel mutations[J]. Diabetes Care，2015，38（11）：2033-2041．
本文引用 [1]
11
Association AD.5.facilitating behavior change and well-being to improve health outcomes：Standards of medical care in diabetes-2020 [J]. Diabetes Care，2020，43（Suppl 1）：S48-S65．
本文引用 [1]
12
Powers MA， Bardsley JK， Cypress M，et al. Diabetes self-management education and support in adults with type 2 diabetes：a consensus report of the American diabetes association，the association of diabetes care & education specialists，the academy of nutrition and dietetics，the American academy of family physicians，the American academy of PAs，the American association of nurse practitioners，and the American pharmacists association[J]. Diabetes Care，2020，43（7）：1636-1649．
本文引用 [1]
13
Evert AB， Dennison M， Gardner CD，et al. Nutrition therapy for adults with diabetes or prediabetes：a consensus report[J]. Diabetes Care，2019，42（5）：731-754．
本文引用 [1]
14
中华医学会内分泌学分会. 肥胖患者的长期体重管理及药物临床应用指南（2024版）[J]. 中华内分泌代谢杂志，2024，40（7）：545-564．
Chinese Society of Endocrinolog.Guideline for chronic weight management and clinical practice of anti-obesity medications（2024 version）[J]. Chin J Endocrinol Metab，2024，40（7）：545-564．
本文引用 [1]
15
Almandoz JP， Wadden TA， Tewksbury C，et al. Nutritional considerations with antiobesity medications[J]. Obesity（Silver Spring），2024，32（9）：1613-1631．
16
Davies MJ， Aroda VR， Collins BS，et al. Management of hyperglycemia in type 2 diabetes，2022. A consensus report by the American diabetes association（ADA） and the European association for the study of diabetes（EASD）[J]. Diabetes Care，2022，45（11）：2753-2786．
本文引用 [1]
17
Rosenstock J， Bain SC， Gowda A，et al. Weekly icodec versus daily glargine U100 in type 2 diabetes without previous insulin[J]. N Engl J Med，2023，389（4）：297-308．
本文引用 [1]
18
Mathieu C， Ásbjörnsdóttir B， Bajaj HS，et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes（ONWARDS 4）：a phase 3a，randomised，open-label，multicentre，treat-to-target，non-inferiority trial[J]. Lancet，2023，401（10392）：1929-1940．
本文引用 [1]
19
Yao HQ， Zhang AQ， Li DL，et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control，body weight，and lipid profile for type 2 diabetes：systematic review and network meta-analysis[J]. BMJ，2024，384：e076410．
本文引用 [1]
20
Emerging Risk Factors Collaboration. Life expectancy associated with different ages at diagnosis of type 2 diabetes in high-income countries：23 million person-years of observation[J]. Lancet Diabetes Endocrinol，2023，11（10）：731-742．
本文引用 [1]
21
American Diabetes Association Professional Practice Committee. obesity and weight management for the prevention and treatment of type 2 diabetes：standards of care in diabetes-2024[J]. Diabetes Care，2024，47（Suppl 1）：S145-S157．
本文引用 [1]
22
Frías JP， Davies MJ， Rosenstock J，et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes[J]. N Engl J Med，2021，385（6）：503-515．
本文引用 [1]
23
Eisenberg D， Shikora SA， Aarts E，et al. 2022 American society of metabolic and bariatric surgery（ASMBS） and international federation for the surgery of obesity and metabolic disorders（IFSO） indications for metabolic and bariatric surgery[J]. Obes Surg，2023，33（1）：3-14．
本文引用 [1]
24
Umpierrez GE， Davis GM， ElSayed NA，et al. Hyperglycemic crises in adults with diabetes：a consensus report[J]. Diabetes Care，2024，47（8）：1257-1275．
本文引用 [1]
25
Filippatos G， Anker SD， Agarwal R，et al. Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes[J]. Circulation，2021，143（6）：540-552．
本文引用 [1]
26
Houeiss P， Njeim R， Tamim H，et al. Urinary 20-HETE：a prospective Non-Invasive prognostic and diagnostic marker for diabetic kidney disease[J]. J Adv Res，2023，44：109-117．
本文引用 [1]
27
Sheng B， Guan ZY， Lim LL，et al. Large language models for diabetes care：Potentials and prospects[J]. Sci Bull（Beijing），2024，69（5）：583-588．
本文引用 [1]
28
Battelino T， Danne T， Bergenstal RM，et al. Clinical targets for continuous glucose monitoring data interpretation：recommendations from the international consensus on time in range[J]. Diabetes Care，2019，42（8）：1593-1603．
本文引用 [1]
29
Slama L， Barrett BW， Abraham AG，et al. Risk for incident diabetes is greater in prediabetic men with HIV than without HIV[J]. AIDS，2021，35（10）：1605-1614．
本文引用 [1]

Comments

PDF(681 KB)

Accesses

Citation

Detail
Sections
Recommended
Copyright © Journal of Chongqing Medical University, All Rights Reserved.
Powered by Beijing Magtech Co. Ltd.

/

〈 〉